-
Tytuł:
-
An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group.
-
Autorzy:
-
Shimada M; Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.; Tohoku University Advanced Research Center for Innovations in Next-Generation Medicine, Sendai, Japan. .
Yoshihara K; Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Chuo, Japan.
Tanigawa T; Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Nomura H; Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, Toyoake, Japan.
Hamanishi J; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Fujiwara S; Department of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Tanabe H; Department of Gynecology, National Cancer Center Hospital East, Kashiwa, Japan.
Kajiyama H; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Showa-ku, Japan.
Mandai M; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Aoki D; Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Enomoto T; Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Chuo, Japan.
Okamoto A; Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo, Japan.
-
Źródło:
-
Journal of gynecologic oncology [J Gynecol Oncol] 2023 May; Vol. 34 (3), pp. e62. Date of Electronic Publication: 2023 Apr 21.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: June 2011-: Seoul : Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe
Original Publication: Seoul : Korean Society of Gynecologic Oncology and Colposcopy, June 2008-
-
MeSH Terms:
-
Carcinoma, Ovarian Epithelial*/drug therapy
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/pathology
Poly(ADP-ribose) Polymerase Inhibitors*/adverse effects
Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use
Female ; Humans ; East Asian People ; Genital Neoplasms, Female/drug therapy ; Genital Neoplasms, Female/therapy ; Genome-Wide Association Study ; Poly(ADP-ribose) Polymerases/therapeutic use
-
References:
-
J Clin Oncol. 2014 May 1;32(13):1302-8. (PMID: 24637997)
Lancet Oncol. 2019 May;20(5):636-648. (PMID: 30948273)
N Engl J Med. 2016 Dec;375(22):2154-2164. (PMID: 27717299)
N Engl J Med. 2012 Apr 12;366(15):1382-92. (PMID: 22452356)
N Engl J Med. 2011 Dec 29;365(26):2484-96. (PMID: 22204725)
Nat Genet. 2020 Jul;52(7):669-679. (PMID: 32514122)
N Engl J Med. 2018 Dec 27;379(26):2495-2505. (PMID: 30345884)
Lancet Oncol. 2017 Sep;18(9):1274-1284. (PMID: 28754483)
N Engl J Med. 2019 Dec 19;381(25):2416-2428. (PMID: 31851799)
N Engl J Med. 2011 Dec 29;365(26):2473-83. (PMID: 22204724)
J Clin Oncol. 2019 Sep 20;37(27):2386-2397. (PMID: 31403859)
J Clin Oncol. 2012 Jun 10;30(17):2039-45. (PMID: 22529265)
N Engl J Med. 2019 Dec 19;381(25):2391-2402. (PMID: 31562799)
J Clin Oncol. 2022 Nov 20;40(33):3878-3881. (PMID: 36150092)
-
Contributed Indexing:
-
Keywords: Epithelial Ovarian Cancer; PARP Inhibitors; Poly(ADP-ribose) Polymerases; Real-world Data
-
Substance Nomenclature:
-
0 (Poly(ADP-ribose) Polymerase Inhibitors)
EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
-
Entry Date(s):
-
Date Created: 20230428 Date Completed: 20230510 Latest Revision: 20230510
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC10157342
-
DOI:
-
10.3802/jgo.2023.34.e62
-
PMID:
-
37116954
-
The development of new treatments for gynecological malignancies has been conducted mainly through collaborative international phase III trials led by the United States and Europe. The survival outcomes of many gynecological malignancies have greatly improved as a result. Recent large-scale genome-wide association studies have revealed that drug efficacy and adverse event profiles are not always uniform. Thus, it is important to validate new treatment options in each country to safely and efficiently provide newly developed treatment options to patients with gynecological malignancies. The Japanese Gynecologic Oncology Group (JGOG) is conducting 5 cohort studies (JGOG 3026, 3027, 3028, 3030, and 3031) to establish real-world data (RWD) of poly(ADP-ribose) polymerase (PARP) inhibitor use in patients with advanced or recurrent epithelial ovarian cancer. The RWD constructed will be used to provide newly developed PARP inhibitors for women with advanced or recurrent ovarian cancer in a safer and more efficient manner as well as to develop further treatment options. In 2022, The JGOG, Korean Gynecologic Oncology Group, Chinese Gynecologic Cancer Society, and Taiwanese Gynecologic Oncology Group established the East Asian Gynecologic Oncology Trial Group to collaborate with East Asian countries in clinical research on gynecologic malignancies and disseminate new knowledge on gynecologic malignancies from Asia. The JGOG will conduct a collaborative integrated analysis of the RWD generated from Asian countries and disseminate real-world clinical knowledge regarding new treatment options that have been clinically implemented.
Competing Interests: No potential conflict of interest relevant to this article was reported.
(© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.)
